STELLANEWS.LIFE（ステラニュース・ライフ）は、科学技術・医療・ライフサイエンスの分野における研究 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学技術・医療・ライフサイエンスの分野における研究

PfizerとAstellasは、シスプラチン不適格の筋層浸潤性膀胱がん（MIBC）を対象に、パドセブ（エンホルツマブ ベドチン）＋キイトルーダ（ペムブロリズマブ）の周術期併用療法がFDAにより承認されたと発表。第3相EV-303試験でEFSとOSの改善が認められた。

The combination of the anti-PD-1 antibody pembrolizumab plus the nectin 4-targeted antibody–drug conjugate enfortumab vedotin (EV) has been shown to improve the outcomes of patients with advanced-stage bladder cancer. Now, data from the phase III EV303/KEYNOTE-905 trial demonstrate the efficacy of this combination as perioperative therapy in patients with resectable disease who are ineligible for or decline neoadjuvant chemotherapy. A total of 344 patients with stage T2–T4a N0M0 or T1–T4a N1M0 bladder cancer who were able to undergo surgery were initially randomly assigned to receive perioperative EV plus pembrolizumab versus observation, following protocol amendments in 2020 and 2022 that first introduced and then prioritized the EV plus pembrolizumab arm. Event-free survival (EFS) was the primary end point. Get Nature+, our best-value online-access subscription Prices may be subject to local taxes which are calculated during checkout